Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Ralph N. Martins, Victor Villemagne, Hamid R. Sohrabi, Pratishtha Chatterjee, Tejal M. Shah, Giuseppe Verdile, Paul Fraser, Kevin Taddei, Veer B. Gupta, Stephanie R. Rainey-Smith, Eugene Hone, Steve Pedrini, Wei Ling Lim, Ian Martins, Shaun Frost, Sunil Gupta, Sid O'Bryant, Alan Rembach, David Ames, Kathryn EllisStephanie J. Fuller, Belinda Brown, Samantha L. Gardener, Binosha Fernando, Prashant Bharadwaj, Samantha Burnham, Simon M. Laws, Anna M. Barron, Kathryn Goozee, Eka J. Wahjoepramono, Prita R. Asih, James D. Doecke, Olivier Salvado, Ashley I. Bush, Christopher C. Rowe, Samuel E. Gandy, Colin L. Masters

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ϵ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.

Original languageEnglish
Pages (from-to)965-992
Number of pages28
JournalJournal of Alzheimer's Disease
Volume62
Issue number3
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Amyloid
Alzheimer Disease
Oxidative Stress
Cohort Studies
Biomarkers
Technology
Peptides
Research
Life Style
Community Health Planning
Apolipoprotein E4
Western Australia
Amyloid Plaques
Caregivers
Dementia
Early Diagnosis
Sleep
Exercise
Diet
Costs and Cost Analysis

Keywords

  • Alzheimer's disease
  • amyloid
  • apolipoprotein E
  • biomarker
  • dementia
  • early diagnosis
  • preclinical

Cite this

Martins, Ralph N. ; Villemagne, Victor ; Sohrabi, Hamid R. ; Chatterjee, Pratishtha ; Shah, Tejal M. ; Verdile, Giuseppe ; Fraser, Paul ; Taddei, Kevin ; Gupta, Veer B. ; Rainey-Smith, Stephanie R. ; Hone, Eugene ; Pedrini, Steve ; Lim, Wei Ling ; Martins, Ian ; Frost, Shaun ; Gupta, Sunil ; O'Bryant, Sid ; Rembach, Alan ; Ames, David ; Ellis, Kathryn ; Fuller, Stephanie J. ; Brown, Belinda ; Gardener, Samantha L. ; Fernando, Binosha ; Bharadwaj, Prashant ; Burnham, Samantha ; Laws, Simon M. ; Barron, Anna M. ; Goozee, Kathryn ; Wahjoepramono, Eka J. ; Asih, Prita R. ; Doecke, James D. ; Salvado, Olivier ; Bush, Ashley I. ; Rowe, Christopher C. ; Gandy, Samuel E. ; Masters, Colin L. / Alzheimer's Disease : A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. In: Journal of Alzheimer's Disease. 2018 ; Vol. 62, No. 3. pp. 965-992.
@article{695f272a764245859c899248070102c7,
title = "Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies",
abstract = "Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ϵ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.",
keywords = "Alzheimer's disease, Aβ, amyloid, apolipoprotein E, biomarker, dementia, early diagnosis, preclinical",
author = "Martins, {Ralph N.} and Victor Villemagne and Sohrabi, {Hamid R.} and Pratishtha Chatterjee and Shah, {Tejal M.} and Giuseppe Verdile and Paul Fraser and Kevin Taddei and Gupta, {Veer B.} and Rainey-Smith, {Stephanie R.} and Eugene Hone and Steve Pedrini and Lim, {Wei Ling} and Ian Martins and Shaun Frost and Sunil Gupta and Sid O'Bryant and Alan Rembach and David Ames and Kathryn Ellis and Fuller, {Stephanie J.} and Belinda Brown and Gardener, {Samantha L.} and Binosha Fernando and Prashant Bharadwaj and Samantha Burnham and Laws, {Simon M.} and Barron, {Anna M.} and Kathryn Goozee and Wahjoepramono, {Eka J.} and Asih, {Prita R.} and Doecke, {James D.} and Olivier Salvado and Bush, {Ashley I.} and Rowe, {Christopher C.} and Gandy, {Samuel E.} and Masters, {Colin L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-171145",
language = "English",
volume = "62",
pages = "965--992",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

Martins, RN, Villemagne, V, Sohrabi, HR, Chatterjee, P, Shah, TM, Verdile, G, Fraser, P, Taddei, K, Gupta, VB, Rainey-Smith, SR, Hone, E, Pedrini, S, Lim, WL, Martins, I, Frost, S, Gupta, S, O'Bryant, S, Rembach, A, Ames, D, Ellis, K, Fuller, SJ, Brown, B, Gardener, SL, Fernando, B, Bharadwaj, P, Burnham, S, Laws, SM, Barron, AM, Goozee, K, Wahjoepramono, EJ, Asih, PR, Doecke, JD, Salvado, O, Bush, AI, Rowe, CC, Gandy, SE & Masters, CL 2018, 'Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies', Journal of Alzheimer's Disease, vol. 62, no. 3, pp. 965-992. https://doi.org/10.3233/JAD-171145

Alzheimer's Disease : A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies. / Martins, Ralph N.; Villemagne, Victor; Sohrabi, Hamid R.; Chatterjee, Pratishtha; Shah, Tejal M.; Verdile, Giuseppe; Fraser, Paul; Taddei, Kevin; Gupta, Veer B.; Rainey-Smith, Stephanie R.; Hone, Eugene; Pedrini, Steve; Lim, Wei Ling; Martins, Ian; Frost, Shaun; Gupta, Sunil; O'Bryant, Sid; Rembach, Alan; Ames, David; Ellis, Kathryn; Fuller, Stephanie J.; Brown, Belinda; Gardener, Samantha L.; Fernando, Binosha; Bharadwaj, Prashant; Burnham, Samantha; Laws, Simon M.; Barron, Anna M.; Goozee, Kathryn; Wahjoepramono, Eka J.; Asih, Prita R.; Doecke, James D.; Salvado, Olivier; Bush, Ashley I.; Rowe, Christopher C.; Gandy, Samuel E.; Masters, Colin L.

In: Journal of Alzheimer's Disease, Vol. 62, No. 3, 01.01.2018, p. 965-992.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Alzheimer's Disease

T2 - A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

AU - Martins, Ralph N.

AU - Villemagne, Victor

AU - Sohrabi, Hamid R.

AU - Chatterjee, Pratishtha

AU - Shah, Tejal M.

AU - Verdile, Giuseppe

AU - Fraser, Paul

AU - Taddei, Kevin

AU - Gupta, Veer B.

AU - Rainey-Smith, Stephanie R.

AU - Hone, Eugene

AU - Pedrini, Steve

AU - Lim, Wei Ling

AU - Martins, Ian

AU - Frost, Shaun

AU - Gupta, Sunil

AU - O'Bryant, Sid

AU - Rembach, Alan

AU - Ames, David

AU - Ellis, Kathryn

AU - Fuller, Stephanie J.

AU - Brown, Belinda

AU - Gardener, Samantha L.

AU - Fernando, Binosha

AU - Bharadwaj, Prashant

AU - Burnham, Samantha

AU - Laws, Simon M.

AU - Barron, Anna M.

AU - Goozee, Kathryn

AU - Wahjoepramono, Eka J.

AU - Asih, Prita R.

AU - Doecke, James D.

AU - Salvado, Olivier

AU - Bush, Ashley I.

AU - Rowe, Christopher C.

AU - Gandy, Samuel E.

AU - Masters, Colin L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ϵ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.

AB - Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E ϵ4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral Aβ.

KW - Alzheimer's disease

KW - Aβ

KW - amyloid

KW - apolipoprotein E

KW - biomarker

KW - dementia

KW - early diagnosis

KW - preclinical

UR - http://www.scopus.com/inward/record.url?scp=85044368934&partnerID=8YFLogxK

U2 - 10.3233/JAD-171145

DO - 10.3233/JAD-171145

M3 - Review article

C2 - 29562546

AN - SCOPUS:85044368934

VL - 62

SP - 965

EP - 992

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -